| New ibrutinib methyl vanillate co-crystal used for treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom macroglobulinemia and small lymphocytic lymphoma | |
| 2023-07-19 | |
| 专利权人 | INTAS PHARM LTD (INTA-Non-standard) |
| 申请日期 | 2023-07-19 |
| 专利号 | IN202321048486-A |
| 成果简介 | NOVELTY - Ibrutinib methyl vanillate co-crystal, is new. USE - Ibrutinib methyl vanillate co-crystal used for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom macroglobulinemia and small lymphocytic lymphoma. No biological data is given. ADVANTAGE - The method provides improved, economical viable and simple preparation of ibrutinib methyl vanillate co-crystal with high yield and purity. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing of the ibrutinib methyl vanillate co-crystal. |
| IPC 分类号 | A61K-031/519 ; A61P-035/00 ; A61P-035/02 ; C07C-051/43 ; C07D-487/04 |
| 国家 | 印度 |
| 专业领域 | 医药卫生 |
| 语种 | 英语 |
| 成果类型 | 专利 |
| 文献类型 | 科技成果 |
| 条目标识符 | http://119.78.100.226:8889/handle/3KE4DYBR/21236 |
| 专题 | 中国科学院新疆生态与地理研究所 |
| 作者单位 | INTAS PHARM LTD (INTA-Non-standard) |
| 推荐引用方式 GB/T 7714 | VADARIYA R J,KUNDARIYA K L,PRAJAPATI U V,et al. New ibrutinib methyl vanillate co-crystal used for treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom macroglobulinemia and small lymphocytic lymphoma. IN202321048486-A[P]. 2023. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论